Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Multimodal deep learning improves recurrence risk prediction in pediatric low-grade gliomas
23
Zitationen
23
Autoren
2024
Jahr
Abstract
BACKGROUND: Postoperative recurrence risk for pediatric low-grade gliomas (pLGGs) is challenging to predict by conventional clinical, radiographic, and genomic factors. We investigated if deep learning (DL) of magnetic resonance imaging (MRI) tumor features could improve postoperative pLGG risk stratification. METHODS: We used a pretrained DL tool designed for pLGG segmentation to extract pLGG imaging features from preoperative T2-weighted MRI from patients who underwent surgery (DL-MRI features). Patients were pooled from 2 institutions: Dana Farber/Boston Children's Hospital (DF/BCH) and the Children's Brain Tumor Network (CBTN). We trained 3 DL logistic hazard models to predict postoperative event-free survival (EFS) probabilities with (1) clinical features, (2) DL-MRI features, and (3) multimodal (clinical and DL-MRI features). We evaluated the models with a time-dependent Concordance Index (Ctd) and risk group stratification with Kaplan-Meier plots and log-rank tests. We developed an automated pipeline integrating pLGG segmentation and EFS prediction with the best model. RESULTS: Of the 396 patients analyzed (median follow-up: 85 months, range: 1.5-329 months), 214 (54%) underwent gross total resection and 110 (28%) recurred. The multimodal model improved EFS prediction compared to the DL-MRI and clinical models (Ctd: 0.85 (95% CI: 0.81-0.93), 0.79 (95% CI: 0.70-0.88), and 0.72 (95% CI: 0.57-0.77), respectively). The multimodal model improved risk-group stratification (3-year EFS for predicted high-risk: 31% versus low-risk: 92%, P < .0001). CONCLUSIONS: DL extracts imaging features that can inform postoperative recurrence prediction for pLGG. Multimodal DL improves postoperative risk stratification for pLGG and may guide postoperative decision-making. Larger, multicenter training data may be needed to improve model generalizability.
Ähnliche Arbeiten
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 · 21.414 Zit.
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
2016 · 15.812 Zit.
The 2007 WHO Classification of Tumours of the Central Nervous System
2007 · 13.912 Zit.
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
2013 · 12.094 Zit.
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
2021 · 11.396 Zit.
Autoren
- Maryamalsadat Mahootiha
- Divyanshu Tak
- Zezhong Ye
- Anna Zapaishchykova
- Jirapat Likitlersuang
- Juan Carlos Pardo
- Aidan Boyd
- Sridhar Vajapeyam
- Rishi Chopra
- Sanjay P. Prabhu
- Kevin X. Liu
- Hesham Elhalawani
- Ali Nabavizadeh
- Ariana Familiar
- Sabine Mueller
- Hugo J.W.L. Aerts
- Pratiti Bandopadhayay
- Keith L. Ligon
- Daphne A. Haas‐Kogan
- Tina Young Poussaint
- Hemin Ali Qadir
- Ilangko Balasingham
- Benjamin H. Kann
Institutionen
- Oslo University Hospital(NO)
- Brigham and Women's Hospital(US)
- Boston Children's Hospital(US)
- Harvard University(US)
- University of Oslo(NO)
- Dana-Farber Cancer Institute(US)
- Dana-Farber Brigham Cancer Center(US)
- Mass General Brigham(US)
- Children's Hospital of Philadelphia(US)
- University of Pennsylvania(US)
- University of California, San Francisco(US)
- Neurological Surgery(US)
- Maastricht University(NL)
- Norwegian University of Science and Technology(NO)